Apolipoproteins and coronary heart disease

  • J. P. Deslypere


Clinical and experimental studies on apolipoprotein composition and atherogenicity are reviewed including case control, angiographic, prospective, and familial studies. Recent studies investigated the value of apolipoprotein measurements in the assessment of coronary hard disease risk. Most of the studies indicate that apo AI and B are strong CHD risk predictors. Apo B seems to be more strongly associated with cardiovascular risk than LDL-C or HDL-C levels. Another result was that the apolipoprotein levels are good indicators of the presene or absence of CHD. Apo B is a good indicator of the severity of disease.


Review of studies apolipoproteins coronary heart disease case control angiographic prospective and familial studies 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Assmann G (ed) (1989) Lipid metabolism disorders and coronary heart disease. MMV Medizin Verlag, MünchenGoogle Scholar
  2. 2.
    Avogaro P, Bittolo Bon G, Cazzalato G (1979) Are apolipoproteins better discriminators than lipids for atherosclerosis? Lancet is 901–903Google Scholar
  3. 3.
    Avogaro P, Bittolo Bon G, Cazzolato G, Rovai E (1980) Relationship between apolipoproteins and chemical components of lipoproteins in survivors of myocardial infarction. Atherosclerosis 37: 69–76PubMedCrossRefGoogle Scholar
  4. 4.
    Barbir M, Wile D, Trayner I, Aber VR, Thompson GR (1988) High prevalence of hypertriglyceridemia and apolipoprotein abnormalities in coronary artery disease. Br Heart J 60: 397–403PubMedCrossRefGoogle Scholar
  5. 5.
    Bittolo Bon G, Cazzolato G, Saccardi M, Kostner GM, Avogaro P (1984) Total plasma apo E and high density lipoprotein apo E in survivors of myocardial infarction. Atherosclerosis 53: 69–75Google Scholar
  6. 6.
    Boerwinkle E, Utermann G (1988) Simultaneous effects of the apo-lipoprotein E polymorphism on apolipoprotein E, apolipoprotein B and cholesterol metabolism. Am J Hum Genet 42: 104–112Google Scholar
  7. 7.
    Brunzell J, Mazzone T, Motulsky A, Albers JJ (1982) Abnormalities in high density lipoprotein composition in familial combined hyperlipidemia. Arteriosclerosis 2: 416–417Google Scholar
  8. 8.
    Brunzell JD, Albers JJ, Chait A (1983) Plasma lipoproteins in familial combined hyperlipidemic and monogenic familial hypertrigylceridemia. J Lipid Res 24: 147–155PubMedGoogle Scholar
  9. 9.
    De Backer G, Hulstaert F, De Munck K, Rosseneu M, Van Parijs L, Damaix M (1986) Serum lipids and apolipoprotein in students whose parents suffered prematurely from a myocardial infarction. Am Heart J 112: 478–484PubMedCrossRefGoogle Scholar
  10. 10.
    De Backer G, Rosseneu M, Deslypere JP (1982) Discriminative value of lipids and apolipoproteins in coronary heart disease. Atherosclerosis 42: 197–203PubMedCrossRefGoogle Scholar
  11. 11.
    Deslypere JP, De Backer G, Rosseneu M, Vermeulen A (1981) Lipid and apoprotein levels in myocardial infarction survivors: a case-control study. Acta Cardiol 27: 95–102Google Scholar
  12. 12.
    Durrington PN, Hant L, Ishola M, Kane J, Stephens WP (1986) Serum apolipoproteins AI and B and lipoproteins in middle aged men with and without previous myocardial infarction. Br Heart J 56: 206–212PubMedCrossRefGoogle Scholar
  13. 13.
    Freedman DS, Srinivasan SR, Shear CL, Franklin FA, Webber LS, Berenson GS (1986) The relation of apolipoproteins AI and B in children to parenteral myocardial infarction. N Engl J Med 315: 721–726PubMedCrossRefGoogle Scholar
  14. 14.
    Gordon DJ, Rifkind B (1989) High density lipoprotein — the clinical implications of recent studies. N Engl J Med 321: 1311–1316PubMedCrossRefGoogle Scholar
  15. 15.
    Grundy S, Vega G (1990) Role of apolipoprotein levels in clinical practice. Arch Int Med 150: 1579–1582CrossRefGoogle Scholar
  16. 16.
    Hamsten A, Walldius G, Szamosi A, Dahlen G, de Faire U (1986) Relationship of angiographically defined coronary artery disease to serum lipoproteins and apolipoproteins in young survivors of myocardial infarction. Circulation 73: 1097–1110Google Scholar
  17. 17.
    Ishikawa T, Fidge N, Thelle DS, Forde OH, Miller NE (1978) The Tromso Heart Study. Serum apolipoprotein AI concentration in relation to future coronary heart disease. Eur J Clin Invest 8: 179–182Google Scholar
  18. 18.
    James RW, Martin B, Pometta D, Grab D (1986) Apoprotein D in a healthy male population and in male myocardial infarction patients and their male first degree relatives. Atherosclerosis 60: 49–53PubMedCrossRefGoogle Scholar
  19. 19.
    Kostner GM (1983) Apoproteins and lipoproteins of human plasma, significance in health and in disease. Adv Lipid Res 20: 1–43PubMedGoogle Scholar
  20. 20.
    Kostner GM, Avogaro P, Cazzolato G (1981) Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis 38: 51–61PubMedCrossRefGoogle Scholar
  21. 21.
    Kottke BA, Zinsmeister A, Holmes D, Kneller R, Hallaway B, Mao S (1986) Apilipoproteins and coronary artery disease. Mayo Clin Proc 61: 313–320PubMedGoogle Scholar
  22. 22.
    Kukita H,1 Hiwada K, Kokubu T (1984) Serum apolipoprotein AI, All and B levels and their discriminative values in relatives of patients with coronary artery disease. Atherosclerosis 51: 261–267Google Scholar
  23. 23.
    Lehtonen A, Marniemi J, Inberg M, Maatela J, Alanen E, Nuttymaki K (1986) Levels of serum lipids, apolipoproteins apoAI and B and pseudocholinesterase activity and their discriminative value in patients with coronary bypass operation. Atherosclerosis 59: 215–221PubMedCrossRefGoogle Scholar
  24. 24.
    Maciejko JJ, Holmes DR, Kottke BA, Zinsmeister AR, Dinh DM, Mao SJ (1983) Apolipoprotein AI as a marker of angiographically assessed coronary artery disease. N Engl J Med 309: 385–389PubMedCrossRefGoogle Scholar
  25. 25.
    Miller NE (1987) Associations of high lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J 113: 589–597PubMedCrossRefGoogle Scholar
  26. 26.
    Murai A, Miyahara T, Fujimoto N (1986) Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis 59: 199–204PubMedCrossRefGoogle Scholar
  27. 27.
    Naito HK (1985) The association of serum lipids, lipoproteins and apolipoproteins with coronary artery disease assessed by coronary arteriography. Ann NY Acad Sci 454: 230–238PubMedCrossRefGoogle Scholar
  28. 28.
    Reinhart R, Gani K, Arndt M, Broste S (1990) Apolipoproteins AI and B as predictors of angiographically defined coronary artery disease. Arch Int Med 150: 1629–1633CrossRefGoogle Scholar
  29. 29.
    Rhoads GG, Dahlen G, Berg K (1986) Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA 256: 2540–2544PubMedCrossRefGoogle Scholar
  30. 30.
    Riesen WF, Mordasini R, Salzmann C, Theler A, Gurtner MP (1980)Google Scholar
  31. Apoproteins and lipids as discriminators of severity of coronary heart disease. Atherosclerosis 37: 157–162Google Scholar
  32. 31.
    Salonen JP, Salonen R, Penttila I (1985) Serum fatty acids, apolipoprotein, selenium and vitamin antioxidants and the risk of death from coronary artery disease. Am J Cardiol 56: 226–231PubMedCrossRefGoogle Scholar
  33. 32.
    Sniderman AD, Wolfson C, Teng B, Franklin FA, Bachorik PS, Kwiterovich PO (1982) Association of hyperapobetalipoproteinemia with endogenous hypertriglyceridemia and atherosclerosis. Ann Intern Med 97: 833–839PubMedGoogle Scholar
  34. 33.
    Wiklund 0, Fager G, Olofsson SO, Wilhelmsson C, Bondgers G (1980) Serum apolipoprotein levels in relation to acute myocardial infarction: determination of apolipoprotein B. Atherosclerosis 37: 631–636Google Scholar
  35. 34.
    Zenker G, Koltringer P, Bone G (1986) Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke 17: 942–945PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1991

Authors and Affiliations

  • J. P. Deslypere
    • 1
  1. 1.Department of EndocrinologyUniversity of GentB-9000 GentBelgium

Personalised recommendations